Mankind Pharma Reinvents Global Supply Chain and Procurement with Accenture

Mankind Pharma, India's fourth-largest pharmaceutical company, has completed a large-scale, multi-year transformation of its global supply chain and strategic procurement function to strengthen access to medicines, improve supply reliability, and support disciplined, scalable growth. Delivered in collaboration with Accenture, the integrated initiative embeds digitally enabled operating models, powered by advanced analytics and AI, across Mankind Pharma's procurement, manufacturing and distribution networks. This is enhancing the company's ability to manage demand volatility, supply disruptions, and regulatory complexities at scale.

This transformation brings together two critical operating pillars into a unified, end-to-end backbone that tightly links planning intelligence with execution performance. Mankind Pharma has reimagined its global supply chain through an integrated planning platform that connects demand forecasting, manufacturing, inventory, and distribution within a near real-time decision framework across more than 25 international markets. Powered by advanced analytics and AI-augmented insights, the platform has strengthened forecast accuracy, improved cross-functional alignment, and enabled faster, more responsive planning and execution. In parallel, the company completed an 18-month overhaul of its strategic sourcing and procurement function, reinforcing cost discipline, governance, and supplier collaboration through standardized processes, digital automation, and analytics-led decision-making.

The impact has been tangible and measurable. The customized planning and execution platform deployed across 30 manufacturing facilities and more than 50 distribution centers, has reduced drug stock-outs by 75 per cent and optimized inventory by up to 20 per cent across Mankind Pharma's global distribution network. The platform has enhanced decision-making, and improved coordination across commercial, manufacturing and supply teams. This has strengthened supply chain performance at scale while maintaining the highest standards of quality and compliance.

Alongside this, the procurement transformation initiative has structurally elevated sourcing as a core business capability for Mankind Pharma. The company clarified sourcing ownership and standardized end-to-end processes to improve efficiency and governance. Digital tools now automate routine activities, enabling teams to focus on strategic decisions and supplier partnerships, while advanced analytics give leadership sharper visibility into spending, supplier performance and supply chain risks. Together, these changes have delivered sustainable cost efficiencies while safeguarding quality, compliance, and supply continuity.

Arjun Juneja, Chief Operating Officer, Mankind Pharma Ltd., said: "Ensuring uninterrupted access to quality medicines today requires value chains that are intelligent, digitally enabled, and resilient by design. At Mankind, we have reimagined the traditional value chain into a life chain-built to serve patients, not just processes. By integrating demand, procurement, manufacturing, inventory management, and execution through advanced analytics and AI-augmented insights, we have strengthened our ability to anticipate demand, manage volatility, and respond with speed and precision across markets. This transformation goes beyond efficiency, delivering sharper visibility, stronger control, and quality and compliance by design. It enables us to scale responsibly and sustainably, reinforcing our commitment to Availability, Quality, and Affordability, while building long-term resilience into our operations."

Jignesh Vora, managing director and lead - Life Sciences, Accenture in India, said, "Working closely with Mankind Pharma, Accenture helped reimagine and strengthen the company's operating model for the long term. By combining AI-led, data-driven capabilities with deep life sciences and supply chain expertise, we enabled a more predictive and resilient supply chain and procurement ecosystem-driving better decision-making at scale, improving access to medicines, and supporting sustainable growth in a volatile and regulated environment."

This global supply chain and strategic procurement transformation reinforces Mankind Pharma's commitment to operational excellence, disciplined execution, and long-term resilience, while remaining anchored to its purpose of improving access to quality and affordable medicines. As healthcare systems continue to evolve, the transformation positions the company to respond with agility, consistency, and scale, strengthening trust among patients, partners, and stakeholders across India and global markets.

Shares of Mankind Pharma Limited was last trading in BSE at Rs. 2082.00 as compared to the previous close of Rs. 2060.30. The total number of shares traded during the day was 3058 in over 445 trades.

The stock hit an intraday high of Rs. 2085.40 and intraday low of 2052.10. The net turnover during the day was Rs. 6356626.00.

Source : Equity Bulls

Keywords

MankindPharma INE634S01028 Pharmaceuticals Accenture